[DOI] [PubMed] [Google Scholar] 124.Ishihara Y., Itoh K., Tanaka M., Tsuji M., Kawamoto T., Kawato S., Vogel C.F.A., Yamazaki T
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes
Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies
This "builds over time" narrative is community-reported and aligns loosely with the synaptogenesis framing, but it is anecdote layered on a mechanism story whose foundational papers were retracted
Continued use for 34 weeks improves pigmentation and uneven tone further
Want to better understand peptide mixing, units, milliliters, and injection volumes